Alliances
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
The M&A moves are expected to increase the oncology pipelines of both companies.
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos’ pipeline.
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
Under the terms of the collaboration and license deal, Gilead will fund Renown IHI’s efforts to sequence and analyze the DNA of 15,000 people who have been diagnosed with NASH or nonalcoholic fatty liver disease in addition to a control group of 40,000 people in Nevada.
Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action.
Bioz, Inc., a Silicon Valley AI data company, is proud to announce the expansion of its partnership with Covaris, the world leader in pre-analytical sample preparation technologies.
Symbio LLC, a client-focused, full-service clinical research organization, has signed a five-year contract with OmniComm Systems, Inc., a leading global provider of clinical data management technology.
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
Clearside Biomedical, Inc. announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.
PRESS RELEASES